HK1105587A1 - Compositions and their uses for lysosomal enzyme deficiencies - Google Patents

Compositions and their uses for lysosomal enzyme deficiencies

Info

Publication number
HK1105587A1
HK1105587A1 HK07110965.3A HK07110965A HK1105587A1 HK 1105587 A1 HK1105587 A1 HK 1105587A1 HK 07110965 A HK07110965 A HK 07110965A HK 1105587 A1 HK1105587 A1 HK 1105587A1
Authority
HK
Hong Kong
Prior art keywords
payload
molecule
lysosomal enzyme
compositions
enzyme deficiencies
Prior art date
Application number
HK07110965.3A
Other languages
English (en)
Inventor
Edward I Ginns
Gary R Ostroff
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of HK1105587A1 publication Critical patent/HK1105587A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HK07110965.3A 2004-09-17 2007-10-10 Compositions and their uses for lysosomal enzyme deficiencies HK1105587A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61087204P 2004-09-17 2004-09-17
PCT/US2005/033300 WO2006032039A2 (en) 2004-09-17 2005-09-19 Compositions and their uses for lysosomal enzyme deficiencies

Publications (1)

Publication Number Publication Date
HK1105587A1 true HK1105587A1 (en) 2008-02-22

Family

ID=36060733

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110965.3A HK1105587A1 (en) 2004-09-17 2007-10-10 Compositions and their uses for lysosomal enzyme deficiencies

Country Status (14)

Country Link
US (2) US8007814B2 (xx)
EP (1) EP1802289B1 (xx)
JP (1) JP5302537B2 (xx)
KR (1) KR20070054246A (xx)
CN (1) CN101052383B (xx)
AT (1) ATE536175T1 (xx)
AU (1) AU2005284727A1 (xx)
BR (1) BRPI0515332A (xx)
CA (1) CA2580537C (xx)
ES (1) ES2375995T3 (xx)
HK (1) HK1105587A1 (xx)
IL (1) IL181748A (xx)
WO (1) WO2006032039A2 (xx)
ZA (1) ZA200701943B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006032039A2 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA2626394A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Yeast cell wall particle for delivering osteoprotegerin-encoding polynucleotide
JP5198290B2 (ja) * 2006-02-02 2013-05-15 グローブイミューン,インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
WO2007109564A2 (en) * 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
US20090022799A1 (en) * 2006-10-06 2009-01-22 Shikha Pramanik Barman Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
US20100111985A1 (en) * 2007-04-25 2010-05-06 Orbis Health Solutions, Llc Vaccine compositions and methods of use
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
JP5292118B2 (ja) * 2009-01-30 2013-09-18 富士フイルム株式会社 蛍光内視鏡システム及び蛍光内視鏡システムの作動方法
ES2614181T3 (es) 2010-08-14 2017-05-30 University Of Massachusetts Partícula de pared celular de levadura para suministro de nanopartículas direccionadas al receptor
KR101619815B1 (ko) 2011-04-04 2016-05-12 주식회사 메디진바이오 리소좀 효소를 유효성분으로 포함하는 뮤코지방증 ii의 예방 또는 치료용 약학 조성물
WO2013018091A1 (en) * 2011-08-04 2013-02-07 Ramot At Tel-Aviv Universitiy Ltd. Particles for the treatment of neurodegenerative diseases
RU2608233C2 (ru) * 2012-06-25 2017-01-17 С.А. Дамм Агент для связывания жиров, полученный из биомассы, образующейся в процессе пивоварения
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP6121561B2 (ja) 2012-12-12 2017-04-26 オービス ヘルス ソリューションズ エルエルシー 組織再生のための組成物および方法
US10335433B2 (en) 2013-04-10 2019-07-02 Mimedx Group, Inc. NDGA polymers and metal complexes thereof
CA2911149A1 (en) * 2013-05-02 2014-11-06 The Chancellor, Masters And Scholars Of The University Of Oxford Glycolipid inhibition using iminosugars
CN106456532B (zh) 2014-03-05 2020-07-24 奥比思健康解决方案有限责任公司 使用酵母细胞壁颗粒的疫苗递送系统
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
CN112315944B (zh) * 2020-12-08 2022-09-02 黄山中皇制药有限公司 一种穿琥宁肠溶干混悬剂的制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (xx) * 1972-01-26 1977-01-27
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160542A (en) * 1978-06-02 1979-07-10 Winters Donald R Post and rail interconnection
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4595660A (en) 1983-03-02 1986-06-17 University Of Delaware Molecular cloning with bifunctional plasmid vectors in Bacillus subtilis, mutants and substantially stably transformed mutants of Bacillus subtilis, and methods for utilizing the transformed mutants
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4663308A (en) * 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) * 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
GB8608964D0 (en) 1986-04-12 1986-05-14 Pannell N A Producing microbially encapsulated materials
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) * 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
EP0393143A4 (en) * 1987-12-23 1991-09-11 Us Commerce Cloned dna for synthesizing unique glucocerebrosidase
US5879680A (en) * 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
CA2002890C (en) 1988-11-14 1999-12-14 Susan Long Expression of dna sequences derived from nocardioform microorganisms
JP2582186B2 (ja) * 1989-05-04 1997-02-19 サウザン リサーチ インスティチュート カプセル封じ法及びその製品
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2067159A1 (en) 1989-09-08 1991-03-09 Spiros Jamas Method for immune system activation
WO1991003495A1 (en) 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for producing soluble glucans
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
JPH0832225B2 (ja) 1990-09-07 1996-03-29 三菱製紙株式会社 マイクロカプセルの製造方法
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022560D0 (en) 1990-10-17 1990-11-28 G B Biotechnology Limited Processing of waste
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
EP0675727B1 (en) * 1992-12-10 2002-04-10 Enzon, Inc. Glycolipid enzyme-polymer conjugates
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP2258726A1 (en) * 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
AUPN398295A0 (en) * 1995-07-05 1995-07-27 Carlton And United Breweries Limited Chemical compounds and processes for their production
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
JPH0967205A (ja) 1995-08-31 1997-03-11 Sumitomo Chem Co Ltd 粒状農薬組成物およびその製造方法
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6420176B1 (en) * 1997-09-15 2002-07-16 Genetic Immunity, Llc. Composition for delivering DNA into antigen presenting cells
US7220427B2 (en) * 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6696272B1 (en) * 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
CA2378776A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US8017742B2 (en) * 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
CA2418030C (en) 2000-08-03 2010-10-26 Martin Sauter Isolation of glucan particles and uses thereof
AU2001294890A1 (en) 2000-09-25 2002-04-02 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
US6476003B1 (en) * 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US6973623B2 (en) 2001-06-14 2005-12-06 International Business Machines Corporation System and method for client refresh mode selection
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
ATE454827T1 (de) 2001-11-15 2010-01-15 San Ei Gen Ffi Inc Mikrokapseln und diese enthaltende oralpräparate
TW200302225A (en) * 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2003273179A1 (en) * 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
GB0212302D0 (en) 2002-05-28 2002-07-10 Isis Innovation Method of selecting targets for gene silencing by RNA interference
AU2003257007A1 (en) 2002-08-01 2004-02-23 Immusonic, Inc. Beta-glucan containing composites, methods for manufacturing and for using such composites
EP1545208A4 (en) 2002-08-13 2006-04-12 Biopolymer Engineering Inc METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
JP2006502167A (ja) * 2002-09-04 2006-01-19 バイオポリマー エンジニアリング,インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
US7018986B2 (en) 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US6740336B2 (en) 2002-10-04 2004-05-25 Mirus Corporation Process for generating multilayered particles
JP2006510731A (ja) 2002-10-24 2006-03-30 マイカップ ピーエルシー 標的化送達
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
JP2006509504A (ja) 2002-12-11 2006-03-23 ユニバーシティー オブ マサチューセッツ 脂肪細胞へのsiRNAの導入方法
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
US7122557B2 (en) * 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7091672B2 (en) 2003-06-10 2006-08-15 Lutron Electronics Co., Inc. High efficiency off-line linear power supply
WO2005032490A2 (en) * 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
SI1711058T1 (sl) * 2004-01-23 2022-02-28 Eden Research Plc, Postopki za uničevanje nematod, ki obsega uporabo terpenske komponente
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006032039A2 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
WO2006048291A2 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US7790693B2 (en) 2004-12-02 2010-09-07 University Of Massachusetts Glucose-transport related genes, polypeptides, and methods of use thereof
CA2626394A1 (en) 2005-10-24 2007-05-03 University Of Massachusetts Yeast cell wall particle for delivering osteoprotegerin-encoding polynucleotide
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
ES2614181T3 (es) 2010-08-14 2017-05-30 University Of Massachusetts Partícula de pared celular de levadura para suministro de nanopartículas direccionadas al receptor

Also Published As

Publication number Publication date
AU2005284727A1 (en) 2006-03-23
ATE536175T1 (de) 2011-12-15
US8007814B2 (en) 2011-08-30
WO2006032039A3 (en) 2007-04-05
US20120039929A1 (en) 2012-02-16
KR20070054246A (ko) 2007-05-28
CA2580537A1 (en) 2006-03-23
ES2375995T3 (es) 2012-03-08
US20060083718A1 (en) 2006-04-20
IL181748A0 (en) 2008-04-13
BRPI0515332A (pt) 2008-07-22
WO2006032039A2 (en) 2006-03-23
EP1802289B1 (en) 2011-12-07
CA2580537C (en) 2015-04-21
JP2008513484A (ja) 2008-05-01
CN101052383A (zh) 2007-10-10
JP5302537B2 (ja) 2013-10-02
US8637045B2 (en) 2014-01-28
IL181748A (en) 2013-12-31
EP1802289A2 (en) 2007-07-04
CN101052383B (zh) 2013-01-30
ZA200701943B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
HK1105587A1 (en) Compositions and their uses for lysosomal enzyme deficiencies
MXPA06014552A (es) Producto y metodos para la distribucion de farmacos.
WO2005117557A3 (en) Expression system
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2006060125A3 (en) Compositions and methods for using radio frequency identifiers in biological sciences
WO2005060697A3 (en) Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2007008861A3 (en) Methods of transferring photovoltaic cells
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
WO2004084950A3 (en) Cell targeting methods and compositions
IN2015DN00255A (xx)
WO2005070090A3 (en) Regulatory t cells suppress autoimmunity
WO2008014200A3 (en) Cyclosporin compositions
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2006023922A3 (en) Compositions containing modified fullerenes
WO2004072249A3 (en) Polyvinylethers for delivery of polynucleotides to mammalian cells
WO2006138735A3 (en) Gel compositions for topical administration
WO2006090291A3 (en) Method for expanding cd4+ cd25+ t regulatory cells
MY151984A (en) Non-anticoagulant polysaccharide compositions
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
WO2007076501A3 (en) Endometriosis cell targeting peptide and uses thereof
MXPA02009275A (es) Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160919